Opko Health licenses hGH-CTP Human Growth Hormone worldwide to Pfizer.
Opko Health Inc. and Pfizer Inc. announced that they have entered into a worldwide agreement for the development and commercialization of OPKO�s long-acting hGH-CTP for the treatment of Growth Hormone Deficiency (GHD) in adults and children, as well as for the treatment of growth failure in children born small for gestational age (SGA) who fail to show catch-up growth by 2 years of age.
hGH-CTP has the potential to reduce the required dosing frequency of human growth hormone to a single weekly injection from the current standard of one injection per day. hGH-CTP is currently in a global phase III trial in adults and a global phase II trial in children and has orphan drug designation in the U.S. and Europe for both adults and children with GHD.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins